---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-032070"
form_type: "8-K"
ticker: "HROW"
cik: "0001360214"
company_name: "HARROW, INC."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T19:43:29.705609+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Harrow Q3 revenue up 22% to $22.8M; FDA approves IHEEZO, narrows net loss

## Summary
- Revenue $22.8M (+22% YoY); net loss narrowed to $6.5M from $8.3M; adjusted EBITDA $2.5M vs. -$0.1M.
- FDA approved IHEEZO (ocular anesthetic NDA) on Sept 27; launch expected to double revenues within 24 months.
- Launched Fortisite (fortified antibiotics) and atropine.com; sold non-ophthalmic product line to become pure-play.
- Core net loss per share ($0.06) improved from ($0.20); revenue per shipping day $355K (+21%).
- Nearly $1M order backlog at quarter end due to supply chain issues; cleared in Q4; scaling production.

## SEC filing metadata
- accession: 0001493152-22-032070
- form_type: 8-K
- ticker: HROW
- cik: 0001360214
- company_name: HARROW, INC.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1360214/000149315222032070/0001493152-22-032070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1360214/000149315222032070/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-032070
- JSON: https://secwatch.observer/filing/0001493152-22-032070.json
- Plain text: https://secwatch.observer/filing/0001493152-22-032070.txt

## Key facts
- Earnings Releases
  HARROW, INC. reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 14, 2022, Harrow Health, Inc. (the “Company”) issued a press release and a letter to stockholders announcing its financial results for the period ended September 30, 2022 and an update on recent corporate events.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1360214/000149315222032070/0001493152-22-032070-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.